Which has higher valuation and earnings, NVS or SNY?

Novartis has higher revenue and earnings than Sanofi. Sanofi is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novartis $54.53B 5.26 $13.98B $6.98 21.55 Sanofi $49.35B 2.12 $8.84B $3.58 12.06

Is NVS or SNY more profitable?

Novartis has a net margin of 24.87% compared to Sanofi's net margin of 16.95%. Novartis' return on equity of 38.82% beat Sanofi's return on equity. Company Net Margins Return on Equity Return on Assets Novartis 24.87% 38.82% 15.16% Sanofi 16.95% 13.39% 7.58%

Does the media prefer NVS or SNY?

In the previous week, Sanofi had 2 more articles in the media than Novartis. MarketBeat recorded 11 mentions for Sanofi and 9 mentions for Novartis. Novartis' average media sentiment score of 0.99 beat Sanofi's score of 0.49 indicating that Novartis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novartis 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sanofi 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, AZN or SNY?

Astrazeneca has higher revenue and earnings than Sanofi. Sanofi is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Astrazeneca $58.74B 4.34 $10.23B $6.66 24.71 Sanofi $49.35B 2.12 $8.84B $3.58 12.06

Is AZN or SNY more profitable?

Astrazeneca has a net margin of 17.19% compared to Sanofi's net margin of 16.95%. Astrazeneca's return on equity of 30.86% beat Sanofi's return on equity. Company Net Margins Return on Equity Return on Assets Astrazeneca 17.19% 30.86% 12.68% Sanofi 16.95% 13.39% 7.58%

Does the media refer more to AZN or SNY?

In the previous week, Astrazeneca had 54 more articles in the media than Sanofi. MarketBeat recorded 65 mentions for Astrazeneca and 11 mentions for Sanofi. Sanofi's average media sentiment score of 0.49 beat Astrazeneca's score of 0.41 indicating that Sanofi is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Astrazeneca 36 Very Positive mention(s) 4 Positive mention(s) 7 Neutral mention(s) 11 Negative mention(s) 7 Very Negative mention(s) Neutral Sanofi 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has preferable valuation & earnings, SNY or NVO?

Novo Nordisk A/S has lower revenue, but higher earnings than Sanofi. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Sanofi, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sanofi $49.35B 2.12 $8.84B $3.58 12.06 Novo Nordisk A/S $46.80B 4.69 $15.51B $4.26 11.53

Is SNY or NVO more profitable?

Novo Nordisk A/S has a net margin of 37.23% compared to Sanofi's net margin of 16.95%. Novo Nordisk A/S's return on equity of 63.31% beat Sanofi's return on equity. Company Net Margins Return on Equity Return on Assets Sanofi 16.95% 13.39% 7.58% Novo Nordisk A/S 37.23% 63.31% 22.19%

Does the media favor SNY or NVO?

In the previous week, Novo Nordisk A/S had 20 more articles in the media than Sanofi. MarketBeat recorded 31 mentions for Novo Nordisk A/S and 11 mentions for Sanofi. Novo Nordisk A/S's average media sentiment score of 0.71 beat Sanofi's score of 0.49 indicating that Novo Nordisk A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sanofi 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Novo Nordisk A/S 21 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive

Which has preferable earnings & valuation, GSK or SNY?

Sanofi has higher revenue and earnings than GSK. Sanofi is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GSK $43.07B 2.41 $7.54B $3.85 13.32 Sanofi $49.35B 2.12 $8.84B $3.58 12.06

Is GSK or SNY more profitable?

GSK has a net margin of 17.82% compared to Sanofi's net margin of 16.95%. GSK's return on equity of 44.28% beat Sanofi's return on equity. Company Net Margins Return on Equity Return on Assets GSK 17.82% 44.28% 11.49% Sanofi 16.95% 13.39% 7.58%

Does the media favor GSK or SNY?

In the previous week, Sanofi had 1 more articles in the media than GSK. MarketBeat recorded 11 mentions for Sanofi and 10 mentions for GSK. Sanofi's average media sentiment score of 0.49 beat GSK's score of 0.29 indicating that Sanofi is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GSK 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Sanofi 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, SNY or ARGX?

Sanofi has higher revenue and earnings than argenex. Sanofi is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sanofi $49.35B 2.12 $8.84B $3.58 12.06 argenex $4.25B 12.58 $1.29B $22.46 38.26

Is SNY or ARGX more profitable?

argenex has a net margin of 31.31% compared to Sanofi's net margin of 16.95%. argenex's return on equity of 44.37% beat Sanofi's return on equity. Company Net Margins Return on Equity Return on Assets Sanofi 16.95% 13.39% 7.58% argenex 31.31% 44.37% 37.55%

Does the media prefer SNY or ARGX?

In the previous week, Sanofi had 6 more articles in the media than argenex. MarketBeat recorded 11 mentions for Sanofi and 5 mentions for argenex. argenex's average media sentiment score of 0.78 beat Sanofi's score of 0.49 indicating that argenex is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sanofi 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral argenex 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Sanofi (SNY) Competitors

$43.18 -0.82 (-1.86%)

Closing price 07/14/2026 04:00 PM Eastern

Extended Trading

$43.10 -0.08 (-0.17%)

As of 08:24 AM Eastern

Compare

SNY vs. NVS, AZN, NVO, GSK, and ARGX

Should you buy Sanofi stock or one of its competitors? MarketBeat compares Sanofi with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Sanofi include Novartis (NVS), Astrazeneca (AZN), Novo Nordisk A/S (NVO), GSK (GSK), and argenex (ARGX). These companies are all part of the "pharmaceutical products" industry.

How does Sanofi compare to Novartis?

Novartis (NYSE:NVS) and Sanofi (NASDAQ:SNY) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, earnings, analyst recommendations, valuation and institutional ownership.

Novartis has a beta of 0.45, indicating that its share price is 55% less volatile than the broader market. Comparatively, Sanofi has a beta of 0.34, indicating that its share price is 66% less volatile than the broader market.

Novartis currently has a consensus target price of $141.20, indicating a potential downside of 6.15%. Sanofi has a consensus target price of $49.50, indicating a potential upside of 14.64%. Given Sanofi's stronger consensus rating and higher probable upside, analysts clearly believe Sanofi is more favorable than Novartis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novartis	2 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.31
Sanofi	0 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.47

13.1% of Novartis shares are owned by institutional investors. Comparatively, 14.0% of Sanofi shares are owned by institutional investors. 0.0% of Novartis shares are owned by insiders. Comparatively, 1.0% of Sanofi shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Novartis pays an annual dividend of $3.08 per share and has a dividend yield of 2.0%. Sanofi pays an annual dividend of $1.76 per share and has a dividend yield of 4.1%. Novartis pays out 44.1% of its earnings in the form of a dividend. Sanofi pays out 49.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

In the previous week, Sanofi had 2 more articles in the media than Novartis. MarketBeat recorded 11 mentions for Sanofi and 9 mentions for Novartis. Novartis' average media sentiment score of 0.99 beat Sanofi's score of 0.49 indicating that Novartis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novartis	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sanofi	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Novartis has higher revenue and earnings than Sanofi. Sanofi is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novartis	$54.53B	5.26	$13.98B	$6.98	21.55
Sanofi	$49.35B	2.12	$8.84B	$3.58	12.06

Novartis has a net margin of 24.87% compared to Sanofi's net margin of 16.95%. Novartis' return on equity of 38.82% beat Sanofi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novartis	24.87%	38.82%	15.16%
Sanofi	16.95%	13.39%	7.58%

Summary

Novartis beats Sanofi on 12 of the 19 factors compared between the two stocks.

How does Sanofi compare to Astrazeneca?

Astrazeneca (NYSE:AZN) and Sanofi (NASDAQ:SNY) are both large-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends, media sentiment and risk.

Astrazeneca has a beta of 0.24, meaning that its share price is 76% less volatile than the broader market. Comparatively, Sanofi has a beta of 0.34, meaning that its share price is 66% less volatile than the broader market.

Astrazeneca pays an annual dividend of $4.34 per share and has a dividend yield of 2.6%. Sanofi pays an annual dividend of $1.76 per share and has a dividend yield of 4.1%. Astrazeneca pays out 65.2% of its earnings in the form of a dividend. Sanofi pays out 49.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Sanofi is clearly the better dividend stock, given its higher yield and lower payout ratio.

Astrazeneca has higher revenue and earnings than Sanofi. Sanofi is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Astrazeneca	$58.74B	4.34	$10.23B	$6.66	24.71
Sanofi	$49.35B	2.12	$8.84B	$3.58	12.06

In the previous week, Astrazeneca had 54 more articles in the media than Sanofi. MarketBeat recorded 65 mentions for Astrazeneca and 11 mentions for Sanofi. Sanofi's average media sentiment score of 0.49 beat Astrazeneca's score of 0.41 indicating that Sanofi is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Astrazeneca	36 Very Positive mention(s)	4 Positive mention(s)	7 Neutral mention(s)	11 Negative mention(s)	7 Very Negative mention(s)	Neutral
Sanofi	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Astrazeneca currently has a consensus target price of $211.00, indicating a potential upside of 28.23%. Sanofi has a consensus target price of $49.50, indicating a potential upside of 14.64%. Given Astrazeneca's stronger consensus rating and higher probable upside, analysts clearly believe Astrazeneca is more favorable than Sanofi.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Astrazeneca	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Sanofi	0 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.47

20.4% of Astrazeneca shares are held by institutional investors. Comparatively, 14.0% of Sanofi shares are held by institutional investors. 1.0% of Sanofi shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Astrazeneca has a net margin of 17.19% compared to Sanofi's net margin of 16.95%. Astrazeneca's return on equity of 30.86% beat Sanofi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Astrazeneca	17.19%	30.86%	12.68%
Sanofi	16.95%	13.39%	7.58%

Summary

Astrazeneca beats Sanofi on 13 of the 19 factors compared between the two stocks.

How does Sanofi compare to Novo Nordisk A/S?

Sanofi (NASDAQ:SNY) and Novo Nordisk A/S (NYSE:NVO) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, profitability, media sentiment, risk and valuation.

14.0% of Sanofi shares are held by institutional investors. Comparatively, 11.5% of Novo Nordisk A/S shares are held by institutional investors. 1.0% of Sanofi shares are held by company insiders. Comparatively, 0.1% of Novo Nordisk A/S shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Sanofi presently has a consensus price target of $49.50, indicating a potential upside of 14.64%. Novo Nordisk A/S has a consensus price target of $65.56, indicating a potential upside of 33.48%. Given Novo Nordisk A/S's higher possible upside, analysts clearly believe Novo Nordisk A/S is more favorable than Sanofi.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanofi	0 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.47
Novo Nordisk A/S	2 Sell rating(s)	16 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.13

Novo Nordisk A/S has lower revenue, but higher earnings than Sanofi. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Sanofi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanofi	$49.35B	2.12	$8.84B	$3.58	12.06
Novo Nordisk A/S	$46.80B	4.69	$15.51B	$4.26	11.53

Sanofi pays an annual dividend of $1.76 per share and has a dividend yield of 4.1%. Novo Nordisk A/S pays an annual dividend of $1.75 per share and has a dividend yield of 3.6%. Sanofi pays out 49.2% of its earnings in the form of a dividend. Novo Nordisk A/S pays out 41.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Novo Nordisk A/S has a net margin of 37.23% compared to Sanofi's net margin of 16.95%. Novo Nordisk A/S's return on equity of 63.31% beat Sanofi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanofi	16.95%	13.39%	7.58%
Novo Nordisk A/S	37.23%	63.31%	22.19%

In the previous week, Novo Nordisk A/S had 20 more articles in the media than Sanofi. MarketBeat recorded 31 mentions for Novo Nordisk A/S and 11 mentions for Sanofi. Novo Nordisk A/S's average media sentiment score of 0.71 beat Sanofi's score of 0.49 indicating that Novo Nordisk A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sanofi	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Novo Nordisk A/S	21 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Sanofi has a beta of 0.34, suggesting that its share price is 66% less volatile than the broader market. Comparatively, Novo Nordisk A/S has a beta of 0.77, suggesting that its share price is 23% less volatile than the broader market.

Summary

Novo Nordisk A/S beats Sanofi on 12 of the 19 factors compared between the two stocks.

How does Sanofi compare to GSK?

GSK (NYSE:GSK) and Sanofi (NASDAQ:SNY) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends, media sentiment and valuation.

Sanofi has higher revenue and earnings than GSK. Sanofi is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GSK	$43.07B	2.41	$7.54B	$3.85	13.32
Sanofi	$49.35B	2.12	$8.84B	$3.58	12.06

GSK has a net margin of 17.82% compared to Sanofi's net margin of 16.95%. GSK's return on equity of 44.28% beat Sanofi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GSK	17.82%	44.28%	11.49%
Sanofi	16.95%	13.39%	7.58%

In the previous week, Sanofi had 1 more articles in the media than GSK. MarketBeat recorded 11 mentions for Sanofi and 10 mentions for GSK. Sanofi's average media sentiment score of 0.49 beat GSK's score of 0.29 indicating that Sanofi is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GSK	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sanofi	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

GSK has a beta of 0.35, meaning that its share price is 65% less volatile than the broader market. Comparatively, Sanofi has a beta of 0.34, meaning that its share price is 66% less volatile than the broader market.

GSK pays an annual dividend of $1.79 per share and has a dividend yield of 3.5%. Sanofi pays an annual dividend of $1.76 per share and has a dividend yield of 4.1%. GSK pays out 46.5% of its earnings in the form of a dividend. Sanofi pays out 49.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

GSK presently has a consensus price target of $53.00, indicating a potential upside of 3.37%. Sanofi has a consensus price target of $49.50, indicating a potential upside of 14.64%. Given Sanofi's stronger consensus rating and higher possible upside, analysts plainly believe Sanofi is more favorable than GSK.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GSK	2 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.10
Sanofi	0 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.47

15.7% of GSK shares are owned by institutional investors. Comparatively, 14.0% of Sanofi shares are owned by institutional investors. 10.0% of GSK shares are owned by insiders. Comparatively, 1.0% of Sanofi shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

GSK beats Sanofi on 10 of the 18 factors compared between the two stocks.

How does Sanofi compare to argenex?

Sanofi (NASDAQ:SNY) and argenex (NASDAQ:ARGX) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, risk, media sentiment, profitability, valuation, dividends and earnings.

Sanofi has higher revenue and earnings than argenex. Sanofi is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanofi	$49.35B	2.12	$8.84B	$3.58	12.06
argenex	$4.25B	12.58	$1.29B	$22.46	38.26

Sanofi has a beta of 0.34, suggesting that its stock price is 66% less volatile than the broader market. Comparatively, argenex has a beta of 0.45, suggesting that its stock price is 55% less volatile than the broader market.

14.0% of Sanofi shares are owned by institutional investors. Comparatively, 60.3% of argenex shares are owned by institutional investors. 1.0% of Sanofi shares are owned by insiders. Comparatively, 2.4% of argenex shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Sanofi had 6 more articles in the media than argenex. MarketBeat recorded 11 mentions for Sanofi and 5 mentions for argenex. argenex's average media sentiment score of 0.78 beat Sanofi's score of 0.49 indicating that argenex is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sanofi	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
argenex	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

argenex has a net margin of 31.31% compared to Sanofi's net margin of 16.95%. argenex's return on equity of 44.37% beat Sanofi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanofi	16.95%	13.39%	7.58%
argenex	31.31%	44.37%	37.55%

Sanofi presently has a consensus target price of $49.50, indicating a potential upside of 14.64%. argenex has a consensus target price of $1,037.61, indicating a potential upside of 20.73%. Given argenex's stronger consensus rating and higher probable upside, analysts plainly believe argenex is more favorable than Sanofi.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanofi	0 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.47
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92

Summary

argenex beats Sanofi on 13 of the 16 factors compared between the two stocks.

Get Sanofi News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SNY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SNY vs. The Competition

Export

Metric	Sanofi	Large Cap Pharma Industry	Medical Sector	NASDAQ Exchange
Market Cap	$106.67B	$328.72B	$6.86B	$12.44B
Dividend Yield	4.01%	2.69%	2.68%	8.42%
P/E Ratio	12.06	29.22	26.94	24.38
Price / Sales	2.12	5.28	521.23	91.92
Price / Cash	6.23	14.00	48.59	59.36
Price / Book	1.30	8.17	10.89	6.33
Net Income	$8.84B	$11.61B	$3.59B	$331.02M
7 Day Performance	0.94%	-2.43%	-1.53%	-0.33%
1 Month Performance	-1.42%	5.22%	2.72%	-1.29%
1 Year Performance	-10.27%	26.44%	28.47%	21.30%

Sanofi Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SNY Sanofi	4.1214 of 5 stars	$43.18 -1.9%	$49.50 +14.6%	-11.1%	$106.67B	$49.35B	12.06	74,846
NVS Novartis	2.6892 of 5 stars	$153.35 -0.5%	$141.20 -7.9%	+24.3%	$293.95B	$54.53B	21.97	75,267	Upcoming Earnings
AZN Astrazeneca	4.6155 of 5 stars	$169.79 -1.1%	$211.00 +24.3%	+14.7%	$266.15B	$58.74B	18.53	96,100	Trending News Analyst Downgrade High Trading Volume
NVO Novo Nordisk A/S	4.2909 of 5 stars	$49.28 -0.4%	$65.56 +33.0%	-28.7%	$220.93B	$46.80B	11.57	69,505	Analyst Downgrade
GSK GSK	3.013 of 5 stars	$52.30 -0.9%	$53.00 +1.3%	+33.7%	$106.76B	$43.07B	13.59	66,841	Trending News Dividend Cut

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SNY) was last updated on 7/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sanofi (SNY) Competitors